Medicine and Dentistry
Neoplasm
100%
Glioblastoma
96%
Ganglioglioma
86%
Central Nervous System
41%
Cerebrospinal Fluid
36%
Surgery
32%
Overall Survival
29%
Next Generation Sequencing
28%
Gene Mutation
26%
Melanoma
24%
Cancer
22%
Diagnosis
22%
Circulating Tumor DNA
21%
Meningioma
20%
Immunohistochemistry
19%
Intracranial Tumor
18%
Oligodendroglioma
18%
Temozolomide
17%
Bevacizumab
17%
Diseases
16%
Primary Central Nervous System Lymphoma
16%
Radiation Therapy
16%
Malignant Neoplasm
14%
Oligoastrocytoma
14%
Epidermal Growth Factor Receptor
13%
Pediatrics
13%
Biological Marker
13%
Pathologist
13%
Astrocyte
12%
Central Nervous System Tumor
11%
Cancer Cell
11%
Medulloblastoma
11%
Histopathology
11%
Brain Metastasis
11%
Pleomorphic Xanthoastrocytoma
10%
Clinical Trial
10%
Intractable Epilepsy
10%
Metabolite
10%
Metastatic Carcinoma
10%
Magnetic Resonance Imaging
9%
Retrospective Study
9%
Brain Biopsy
9%
Methylation
8%
Biopsy Technique
8%
Tumor Progression
8%
Progression Free Survival
7%
Pontine Glioma
7%
Gut Microbiome
7%
Tumor Recurrence
7%
Morphology
7%
Keyphrases
Glioblastoma
69%
Genetic Modification
47%
Isocitrate Dehydrogenase 1 (IDH1)
43%
Overall Survival
33%
Tumor
31%
Central Nervous System Tumors
28%
Glioma
26%
Immunohistochemistry
26%
IDH-mutant Glioma
24%
Next-generation Sequencing
23%
Brain Tumor
22%
Primary Central Nervous System Lymphoma (PCNSL)
20%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
20%
Infiltrating Glioma
18%
Central Nervous System
18%
High-grade Glioma
18%
Cerebrospinal Fluid
18%
Bevacizumab
16%
Meningioma
15%
Circulating Tumor DNA (ctDNA)
14%
Histopathological Features
14%
Diffuse Intrinsic Pontine Glioma
13%
Surrogate Marker
13%
Recurrent Glioblastoma
13%
Oligodendroglioma
13%
IDH mutation
13%
Astrocytoma
12%
Neoplasms
12%
Molecular Alterations
12%
Clinical Characteristics
12%
IDH2 mutation
12%
Molecular Characteristics
12%
IDH-wildtype
11%
Survival Outcomes
11%
Melanoma
11%
Prognostic Factors
10%
Temozolomide
10%
Stereotactic Radiosurgery
10%
Extent of Resection
10%
Nicotinic Acetylcholine Receptor (nAChR)
10%
Multi-institutional
10%
Multivariable
10%
Survival Analysis
9%
Hazard Ratio
9%
Tumor Recurrence
9%
Adult Patients
8%
World Health Organization Grade
8%
Central Nervous System Malignancies
8%
Tumor Subtype
8%
United States
8%